Rundo Med-Tech Partners with Baidu to Advance Digital Clinical Trials
Shanghai-based Contract Research Organization (CRO) Rundo Pharmaceutical R&D (Shanghai) Co., Ltd (Rundo Med-Tech) has entered...
China’s NMPA Releases 60th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 60th batch of reference drugs for...
China Medical System Licenses Botulinum Toxin from South Korea’s BMI Korea
China Medical System Holdings (CMS; HKG: 0867) has announced the establishment of a licensing agreement...
Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has held a national market...
Betta Pharmaceuticals Raises $140.5M for Drug Industrialization Base in Zhejiang
China’s Betta Pharmaceuticals Co., Ltd. (SHE: 300558) plans to raise RMB 1 billion ($140.5 million)...
China’s Volume-Based Procurement Cuts High-Value Medical Consumables Costs by 84%
The national high-value medical consumables alliance procurement office has released the results of the third...
Everest Medicines’ Xerava Approved in Hong Kong for Complicated Intra-Abdominal Infections
Everest Medicines Limited (HKG: 1952), a China-based biopharmaceutical company, has announced that it has received...
Ascletis Pharma Doses First Patient in Phase II Study of ASC41 for NASH
Ascletis Pharma Inc. (HKG: 1672), a China-based biopharmaceutical company, has announced that the first patient...
Transcenta’s TST004 Receives FDA IND Clearance for IgAN Treatment
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received Investigational New Drug...
Connect Biopharma’s CBP-201 Shows Positive Results in Atopic Dermatitis Study
China-based Connect Biopharmaceuticals Ltd has announced the topline results of a pivotal clinical study for...
Kira Pharmaceuticals Gets FDA Green Light for Phase II Study of KP104 in SLE-TMA
Kira Pharmaceuticals, a Sino-US biotech company, has announced that it has received approval from the...
BGI Genomics Added to US Defense Department’s Investment Ban List
BGI Genomics Co., Ltd, a leading Chinese gene sequencing firm, has reportedly been added to...
Humanwell Healthcare’s Remimazolam Receives NMPA Approval for Bronchoscopy Use
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received another...
Biosyngen’s First-in-Class Drug Candidate BRG01 Accepted for IND Review
Biosyngen has announced that its investigational new drug (IND) filing for the first-in-class (FIC) drug...
Zai Lab Reports Strong Revenue Growth in 2022 Interim Results
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has released its 2022 interim...
Alphamab Oncology’s KN019 Achieves Primary Endpoint in Phase II RA Study
Suzhou-based biotech Alphamab Oncology (HKG: 9966) has announced that its China-based Phase II KN019-201 study,...
WuXi Biologics Partners with neoX Biotech to Advance AI-Driven Drug Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
Luye Pharma’s Shandong Boan Partners with Shanghai Pharmaceutical for Biologics Manufacturing
China-based Luye Pharma Group (HKG: 2186) has announced that its controlling subsidiary, Shandong Boan Biotechnology...
Staidson’s STSP-0601 Receives Clinical Trial Approval for Hemophilia Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...
Henlius Biotech Gets FDA Nod for HLX07 Clinical Study in CSCC
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the US...